Franklin Biotechnology Discovery Fund Fundamentals
| FRBRX Fund | USD 147.44 1.08 0.74% |
Franklin Biotechnology Discovery fundamentals help investors to digest information that contributes to Franklin Biotechnology's financial success or failures. It also enables traders to predict the movement of Franklin Mutual Fund. The fundamental analysis module provides a way to measure Franklin Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Franklin Biotechnology mutual fund.
Franklin |
Franklin Biotechnology Discovery Mutual Fund Price To Sales Analysis
Franklin Biotechnology's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Franklin Biotechnology Price To Sales | 6.21 X |
Most of Franklin Biotechnology's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Franklin Biotechnology Discovery is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Franklin Biotechnology Discovery has a Price To Sales of 6.21 times. This is much higher than that of the Franklin Templeton Investments family and significantly higher than that of the Health category. The price to sales for all United States funds is notably lower than that of the firm.
Franklin Biotechnology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Franklin Biotechnology's current stock value. Our valuation model uses many indicators to compare Franklin Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Franklin Biotechnology competition to find correlations between indicators driving Franklin Biotechnology's intrinsic value. More Info.Franklin Biotechnology Discovery is one of the top funds in price to earning among similar funds. It also is one of the top funds in price to book among similar funds fabricating about 0.23 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Franklin Biotechnology Discovery is roughly 4.37 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Franklin Biotechnology's earnings, one of the primary drivers of an investment's value.Franklin Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Franklin Biotechnology's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the mutual funds which would be a good addition to a portfolio. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics of similar companies.Franklin Biotechnology is currently under evaluation in price to sales among similar funds.
Fund Asset Allocation for Franklin Biotechnology
The fund consists of 98.75% investments in stocks, with the rest of investments allocated between different money market instruments and various exotic instruments.Asset allocation divides Franklin Biotechnology's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Franklin Fundamentals
| Price To Earning | 19.51 X | ||||
| Price To Book | 4.46 X | ||||
| Price To Sales | 6.21 X | ||||
| Total Asset | 833.93 M | ||||
| Year To Date Return | 6.55 % | ||||
| One Year Return | 13.09 % | ||||
| Three Year Return | 4.67 % | ||||
| Five Year Return | 3.81 % | ||||
| Ten Year Return | 17.44 % | ||||
| Net Asset | 1.42 B | ||||
| Cash Position Weight | 1.04 % | ||||
| Equity Positions Weight | 98.75 % |
About Franklin Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Franklin Biotechnology Discovery's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology Discovery based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Under normal market conditions, the fund invests at least 80 percent of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20 percent of its net assets in equity or debt securities of any type of issuer. It is non-diversified.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Franklin Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |